Abstract TAR DNA binding protein-43 (TDP-43) immunoreactive neuronal inclusions are detected in 20-30% of Alzheimer disease (AD) brains, but the distribution of this pathology has not been rigorously studied. In this report, we describe region-speciWc distribution and density of TDP-43 positive neuronal cytoplasmic inclusions (NCIs) in clinically demented individuals with high probability AD pathology, all with Braak neuroWbrillary tangle stages of V or VI. Sections of hippocampus, amygdala, as well as temporal, frontal, and parietal neocortex, were analyzed with TDP-43 immunohistochemistry, and the density of NCIs was assessed using a semiquantitative scoring method. Of the 29 cases, six had TDP-43 positive NCIs in the amygdala only and seven had TDP-43 inclusions restricted to amygdala and hippocampus. In 16 cases, TDP-43 immunoreactivity was more widespread, aVecting temporal, frontal or parietal neocortex. These Wndings indicate that medial temporal lobe limbic structures are vulnerable to TDP-43 pathology in advanced AD, and that the amygdala appears to be the most susceptible region. The distribution of the lesions in this cross-sectional analysis may suggest a progression of TDP-43 pathology in AD, with limbic structures in the medial temporal lobe aVected Wrst, followed by higher order association cortices.
Introduction
TAR DNA binding protein-43 (TDP-43) has been identiWed as a major ubiquitinated protein in frontotemporal lobar degeneration with ubiquitin-positive, tau-and alphasynuclein negative inclusion bodies (FTLD-U), frontotemporal lobar degeneration with motor neuron disease (FTLD-MND), and amyotrophic lateral sclerosis (ALS) [6, 12, 22] . Subsequent studies have indicated that TDP-43 immunoreactive inclusion bodies can be detected in other neurodegenerative disorders, including Alzheimer disease (AD) [1, 13] , Parkinson disease dementia and dementia with Lewy bodies [21] , and in parkinsonism-dementia complex and ALS of Guam [9] . TDP-43 immunoreactive inclusion bodies can be classiWed as neuronal intranuclear inclusions (NIIs), neuronal cytoplasmic inclusions (NCIs), and dystrophic neurites (DNs) [6] . The relative abundance and distribution of ubiquitin-immunoreactive NCIs, DNs, and NII have been used in several schemes to subtype FTLD-U [14, 18, 23] , but their signiWcance in non-FTLD neurodegenerative disorders remains unclear. We have previously identiWed a subgroup of patients with clinical dementia and advanced AD who had TDP-43 immunoreactivity in the hippocampus and characterized the clinical phenotypes associated with these patients [13] . While the presence of hippocampal TDP-43 immunoreactivity readily identiWes a select group of patients [1] , the region-speciWc distribution of TDP-43 immunoreactivity beyond the hippocampus has only been examined in one previous study [1] . In that study, cases were classiWed as limbic predominant and diVuse according to the distribution of TDP-43 in limbic or neocortical areas, analogous to classiWcation of -synuclein pathology in Lewy body disorders [16] . Involvement of the amygdala was not addressed in that study [1] . Furthermore, it is not known if involvement of the hippocampus is always present in cases with TDP-43 immunoreactivity. Here, we characterize the distribution of TDP-43 immunoreactivity in frontal, temporal, and parietal neocortical regions, and identify cases in which the amygdala is the only region aVected.
Materials and methods
The Mayo Clinic Autopsy Database from January 1, 2000, to December 31, 2006, was searched for patients with clinical dementia and a pathologic diagnosis of high probability AD based on NIA-Reagan criteria [11] and Braak neuroWbrillary tangle stages of V or VI [4] . All cases had been previously examined by an experienced neuropathologist (JEP). Other pathologic processes were excluded with immunohistochemistry for neuroWlament protein, ubiquitin, -synuclein, and phospho-tau. In each case, Braak staging was performed and AD was diagnosed.
Sections from the medial temporal lobe at the level of the lateral geniculate body (including hippocampus, entorhinal cortex, occipitotemporal gyrus, and usually inferior temporal gyrus) were previously analyzed with TDP-43 immunohistochemistry (1:2,000, ProteinTech Group, Chicago, IL) [13] . AD cases with TDP-43 immunoreactivity in the hippocampus were then analyzed for TDP-43 pathology in multiple brain regions, including neocortical regions (frontal, temporal, and parietal) and amygdala. When available, sections from the medulla containing hypoglossal nucleus were also analyzed. In addition to these cases, 22 cases of high probability AD, previously found to be negative for hippocampal TDP-43 immunoreactivity, were also screened with TDP-43 immunohistochemistry of amygdala as well as frontal, temporal, and parietal neocortices. Five cases of Pick disease, six cases of corticobasal degeneration, one case of frontotemporal dementia with parkinsonism linked to chromosome 17, and three cases of Creutzfeldt-Jakob disease were included as control cases. TDP-43 immunoreactivity was considered to be positive only if NCIs were identiWed. The intensity of TDP-43 immunoreactivity was graded semiquantitatively by the density of NCIs with the following scheme: 0 = no NCIs identiWed in the entire section; 0.5 = 1-5 NCIs in the entire section; 1 = an average of one NCI identiWed per Wve high power Welds (400£); 2 = an average of one NCI in every high power Weld; 3 = multiple NCIs identiWed in each high power Weld. The presence of any TDP-43 immunoreactivity in DNs and NII also was noted. For all cases, the density of neuroWbrillary tangles and neuritic plaques was also analyzed semiquantitatively in the amygdala according to CERAD guidelines [19] .
Statistical analysis
Statistical analyses were performed using the JMP computer software (JMP Software, version 6.0.0; SAS Institute Inc., Cary, NC, USA) with statistical signiWcance set at P < 0.05. Student's t test was used to compare the average density of cortical NCIs between temporal cortex and extratemporal cortex (the higher score between frontal and parietal cortex was used for analysis). Linear regression was used for correlational analysis between the density of temporal NCIs and the number of extratemporal cortical region involvement. Chi-square test and Fisher's exact test were used to analyze the diVerence in additional pathology (hippocampal sclerosis and Lewy bodies).
Results
Twenty-three patients with advanced AD were initially identiWed to have TDP-43 positive NCIs in the hippocampal dentate gyrus. In this group, the median age at death was 88 years (Table 1) , with nine patients at or over the age of 90 years at death. Clinically, 22 patients (96%) carried the antemortem diagnosis of clinically probable AD, and one was given the diagnosis of amnestic mild cognitive impairment 5 years prior to autopsy.
All cases of advanced AD with hippocampal NCIs had prominent TDP-43 positive NCIs in the amygdala (Fig. 1a) , but a variable number of TDP-43 positive NCIs in the hippocampal dentate gyrus [13] . All but three cases also had prominent NCIs in the entorhinal cortex (Table 1) . Semiquantitative analysis of TDP-43-positive cases showed the amygdala to have the highest density of NCIs of all regions examined (Table 1) . Among the 23 cases, seven cases had TDP-43 positive NCIs restricted to the amygdala and hippocampus. An additional 16 cases had TDP-43 positive NCIs in neocortex, limited to the temporal cortex in nine cases (Fig. 1b) , and aVecting frontal or parietal or both in addition to the temporal lobe in seven cases (Fig. 1c) . The temporal lobe had a higher density of NCIs than any other neocortical regions (P < 0.001). There was a positive association between the semiquantitative density of TDP-43 positive NCIs in the temporal cortex and the number of additional neocortical regions involved (P < 0.01, R 2 = 0.30). None of the cases in which medulla was examined (N = 10) had any TDP-43 positive NCIs detected in the hypoglossal nucleus.
Of the 22 additional cases without TDP-43 immunoreactivity in the hippocampus, six cases had TDP-43 positive NCIs limited to the amygdala (Fig. 1d) . The density of NCIs in the amygdala was highly variable for amygdalaonly cases compared with the uniformly abundant NCIs in the amygdala of cases that also had TDP-43 immunoreactivity in the hippocampus ( Table 2) . None of the 15 control cases had TDP-43 positive NCIs in the amygdala or elsewhere.
The six cases of amygdala-only TDP-43 were added to the 23 cases in which TDP-43 immunoreactivity was detected in the hippocampus. The 29 cases fell into four main groups based on the distribution of TDP-43 immunoreactivity: amygdala-only (n = 6), amygdala plus hippocampus (n = 7), temporal (including amygdala, hippocampus, and temporal neocortex, n = 9), and temporal-plus (additional extra-temporal involvement in the frontal or parietal neocortex, n = 7). Semiquantitative counts of neuritic plaques and neuroWbrillary tangles in the amygdala of these cases were always frequent, regardless of the presence or absence of TDP-43 positive NCIs. No correlation was found between the semiquantitative count of AD pathology and TDP-43 positive NCIs in the amygdala, although a ceiling eVect of AD pathology could not be excluded.
Discussion
In this study of patients with clinical dementia and advanced pathologic changes of AD, we demonstrate the distribution of TDP-43 immunoreactive NCIs and show that the amygdala is the most frequently aVected region. In addition, the amygdala had the most abundant TDP-43 pathology for cases in which TDP-43 immunoreactivity was detected in other regions. In a small number of cases (n = 6), TDP-43 immunoreactivity was detected only in the amygdala. In the 23 cases with TDP-43 immunoreactivity in the hippocampus as well as the amygdala, involvement of cortical areas was most often detected in temporal lobe, followed by frontal and parietal lobes. Moreover, there was a correlation between the semiquantitative score of temporal neocortical TDP-43 pathology and the extent of extratemporal neocortical involvement. Therefore, analysis of the temporal lobar structures, especially the amygdala, remains critical in the identiWcation of TDP-43-associated pathology in AD. Survey of hippocampal or neocortical regions alone would most likely underestimate the number of cases with TDP-43 pathology. The prominent TDP-43 involvement of medial temporal lobe structures with less often spread to other cortical areas can be classiWed as "limbic" or "diVuse" in AD [1] , with the diVuse-type more frequently associated with pathology unique to FTLD-U such as NIIs. Such a stepwise spread may reXect diVerences in intrinsic susceptibility to TDP-43-associated pathology between neuronal populations, staged degeneration of neurons in associated networks, nonspeciWc vulnerability to inclusion body formation in neurons aVected by a primary neurodegenerative process such as AD, or a combination of these processes. As only a small percentage of TDP-43 positive inclusions were positive for phospho-tau [1] , this pattern likely does not represent nonspeciWc immunoreactivity in AD-associated intranuclear pathology. It is not known if this pattern of TDP-43 copathology holds true in neurodegenerative disorders with only TDP-43 pathology such as FTLD-U and ALS. An analogous situation exists for -synuclein in Parkinson disease compared to -synuclein pathology occurring in the setting of advanced AD. In the former, there is a predictable progression of pathology from brainstem to limbic lobe to cortex [5] , while in AD some cases havesynuclein pathology relatively restricted to the medial temporal lobe structures [25] . The cellular colocalization of tau and TDP-43 originally noted in AD [1] has now been shown to extend to AD cases with Lewy bodies, and some neurons show codeposition of all three proteins [10] . It remains to be determined whether a similar pattern of TDP-43 pathologic distribution we report here exists in Lewy body diseases.
While a staging system of TDP-43 pathology has not been proposed for the primary TDP-43-proteinopathies (FTLD-U and ALS), several lines of evidence point to possible early involvement of amygdala in these disorders. Clinically, severe atrophy of the medial temporal lobe structures, including amygdala and hippocampus, is common in clinically diagnosed behavioral variant frontotemporal dementia and in semantic dementia [7, 8] . Amygdala atrophy is also common in pathologically conWrmed FTLD-U [3, 17] . At autopsy, some cases of ALS also have ubiquitin-positive pathology and neuronal loss in the amygdala [2] . The extent of ubiquitin-immunoreactive inclusions and neuronal loss also correlate with the severity of clinical cognitive impairment in ALS [15, 20, 26] . Thus, TDP-43 pathology in the amygdala may represent one of the earliest stages of TDP-43-associated neurodegeneration.
It remains unknown if the presence of TDP-43 immunoreactivity in advanced AD has any clinical signiWcance. Preliminary studies on this same cohort suggest that it is associated with poorer cognitive performance [13] , although it is diYcult to determine the cognitive burden of region-speciWc TDP-43 pathology such as amygdala-only TDP-43 NCIs. It is unlikely that TDP-43 pathology in AD is merely related to severity of AD pathology, as the AD cases in this study that lacked TDP-43 immunoreactivity had similar AD pathology based upon CERAD plaque and tangle scores and Braak neuroWbrillary tangle staging. It may be diYcult to unequivocally assign a clinical signiWcance to a particular type of pathology in cases with mixed pathologies, and this is true not only for TDP-43 immunoreactivity, but also for ischemic-vascular lesions, Lewy bodies, and hippocampal sclerosis [24] . What can be said is that cases with mixed pathologies usually have more severe clinical phenotype [13, 24] . An approach that might be successful at parsing the contribution of TDP-43 pathology to the clinical syndrome is to examine clinical presentations of patients with and without TDP-43 immunoreactivity who have intermediate-or low-likelihood AD type pathology.
In summary, we present a study on regional distribution of TDP-43-associated pathology in advanced AD. We Wnd that the amygdala is the most frequently aVected regions and usually the most severely aVected, suggesting that it may be the earliest aVected region in such cases. We hypothesize that TDP-43-associated cortical pathology may spread from limbic structures in the medial temporal lobe (amygdala and hippocampus) to multimodal association cortices in temporal lobe and then to frontal and parietal lobes. How subcortical structures (e.g., basal ganglia, thalamus, and brainstem) play into this scheme will require additional studies.
